Zacks.com on MSN2d
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyCassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints ...
SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.
Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...
We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other best ...
Cassava Sciences, Inc. (SAVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...
Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback